Hims & Hers stock fell 12.6% in after-hours trading Friday after the FDA warned it will take action against companies mass-marketing unapproved compounded GLP-1 drugs. The agency is targeting products like the $49/month compounded semaglutide pill HIMS recently launched. Novo Nordisk also issued a statement calling the HIMS offering an unauthorized knockoff and said they plan to pursue legal action. HIMS claims their platform provides necessary access for patients.